Physician profile
Lori Thompson
NPI 1316467749
$4,205.97
in general payments reported to CMS, 2019-2025
24 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $603 · 2022: $1,087 · 2023: $1,158 · 2024: $904 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,431 · Education: $85.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,430.54 |
| Education | $85.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $580.53 | 2021-2024 | |
| Abbvie INC. | $532.11 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $468.93 | 2022-2025 | Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $295.03 | 2022-2025 | Caplyta |
| Alkermes, INC. | $272.24 | 2022-2025 | Aristada, Vivitrol, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $253.71 | 2022-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $251.88 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $246.07 | 2021-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $209.62 | 2022-2024 | Quviviq |
| Lundbeck LLC | $155.62 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $136.10 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $131.49 | 2021-2025 | Hetlioz, Fanapt |
| E.R. Squibb & Sons, L.L.C. | $123.75 | 2024 | Cobenfy |
| Bausch Health US, LLC | $96.34 | 2022-2024 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $91.47 | 2022-2024 | Dyanavel Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $82.19 | 2022-2023 | Spravato |
| Neos Therapeutics, LP | $54.56 | 2022-2024 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $50.83 | 2022-2023 | Belsomra |
| Corium, LLC | $38.22 | 2022 | |
| Axsome Therapeutics, INC. | $34.78 | 2023-2024 | Auvelity |
| Noven Therapeutics, LLC | $33.73 | 2023 | Xelstrym |
| Boston Scientific Corporation | $27.75 | 2025 | Wavewriter Alpha Prime 16 |
| Almatica Pharma LLC | $19.70 | 2023 | Loreev Xr, Sertraline Hcl |
| Brainsway USA INC | $19.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.